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Background. Jugular bulb oxygen saturation (SjVO2) is a surrogate marker for global cerebral
oxygenation. The effect of milrinone on SjVO2 and the cerebrovascular carbon dioxide reactivity
(CCO2R) was investigated.
Methods. Thirty patients scheduled for coronary artery bypass graft surgery (CABG) were
studied prospectively. After sternotomy, normoventilation (at T1; PaCO2=4.7–5.0 kPa) and hyper-
ventilation (at T2; PaCO2=3.3–3.7 kPa) were induced and the changes in SjVO2 (DSjVO2) and PaCO2
(DPaCO2), and DSjVO2/DPaCO2 (CCO2R) were measured. After normoventilation was re-estab-
lished (at T3), milrinone 50 mg kg
1 was given (at T4), followed by hyperventilation (at T5), and
DSjVO2, DPaCO2 and CCO2R were measured.
Results. After milrinone administration at normoventilation (T3 and T4), cardiac index and mixed
venous oxygen saturation increased, while mean arterial pressure and systemic vascular resis-
tance index decreased, without a significant change in SjVO2. Before milrinone administration (T1
and T2), hyperventilation decreased PaCO2 and SjVO2, and DSjVO2 showed positive linear correla-
tion with DPaCO2. After milrinone administration (T4 and T5), hyperventilation decreased PaCO2
and SjVO2, and DSjVO2 showed positive linear correlation with DPaCO2. There was no significant
difference in CCO2R before and after milrinone administration (13.3 (5.7)% kPa
1 and 12.3 (3.9)%
kPa1, respectively).
Conclusions. Although milrinone induced significant haemodynamic changes, SjVO2 and CCO2R
were unchanged during its administration.
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Milrinone is a powerful inodilator which increases the level
of cyclic adenosine monophosphate (cAMP) through selec-
tive inhibition of the low-Km cAMP-specific phosphodi-
esterase (PDE3) in cardiac and vascular smooth muscle.1 2
It has been used widely during cardiac surgery and in severe
heart failure.3 4
Milrinone is known to affect the central nervous system
by increasing cerebral blood flow (CBF)5–8 and preventing
chronic cerebral vasospasm after intracranial haemor-
rhages.9 10 However, most previous studies have been per-
formed in animals5–8 or in patients with a central nervous
system deficit.11
The aim of this study was to investigate the effect of
milrinone on jugular bulb oxygen saturation (SjVO2) and
the cerebrovascular carbon dioxide reactivity (CCO2R) in
patients undergoing coronary artery bypass graft surgery
(CABG).
Methods
With the approval of the institutional review board, this
prospective study was performed on 30 patients undergoing
CABG, with their written consent, between April 2003 and
August 2003. Patients known to have clinically significant
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preoperative renal or neurological abnormalities, chronic
pulmonary disease, a history of carotid artery stenosis or
endarterectomy, or severely impaired left ventricular func-
tion (ejection fraction <40%) were excluded from the study.
All patients were premedicated with morphine 0.05–0.1
mg kg1 i.m. Five ECG leads were attached, and leads II and
V5 were monitored continuously after the patients arrived
in the operating room. A 20-G radial artery catheter was
inserted to measure arterial blood pressure and arterial
blood gases. A thermodilutional pulmonary artery catheter
(Swan-Ganz CCOmbo/SvO2 Model 744HF75, Baxter
Healthcare Corporation, Irvine, CA) for monitoring contin-
uous cardiac output (CO) and mixed venous oxygen satura-
tion (SvO2 ) was inserted in the right internal jugular vein via
a 9.0-Fr introducer (AVA HF, Baxter Healthcare Corpora-
tion, Irvine, CA). Anaesthesia was induced with midazolam
2.0–3.0 mg, sufentanil 1.0–1.5 mg kg1 and rocuronium
50 mg, and maintained with a continuous infusion of
sufentanil 0.2–0.3 mg kg1 h1, rocuronium 20–30 mg
h1 and inhalation of low-dose isoflurane (under 0.5%) in
oxygen (50%) with air. For SjvO2 measurement, an 18-G
central venous catheter was inserted into the left internal
jugular vein in a cephalad direction via a modified Seldinger
technique and, when resistance was sensed, the catheter was
withdrawn about 1–2 mm. The positioning of the jugular bulb
catheter tip was confirmed radiographically in the operating
room. The correct position for the catheter tip was cranial to a
line extending from the atlanto-occipital joint space and
caudal to the lower margin of the orbit. Samples of jugular
bulb blood were drawn at a rate of 1 ml min1 to reduce the
chance of extracerebral blood contamination. After the
induction of anaesthesia, the concordance between arterial
carbondioxidepressure (PaCO2 ) and end-tidal carbon dioxide
pressure (E0CO2 ) was measured, and the mechanical ventila-
tion was controlled to maintain normocarbia (PaCO2=4.7–5.0
kPa). Arterial oxygen saturation (SaO2 ), end-expiratory iso-
flurane concenturation (ET-Isof) and nasopharyngeal
temperature (Temp) were monitored during the study. The
depthofanaesthesiawasmonitoredbyabispectral indexscore
(BIS) monitor (A-200 BIS monitor, Aspect Medical System
Inc., Newton, MA). A transoesophageal echocardiographic
probe was inserted to monitor ventricular wall motion from
the transgastric short-axis view at the mid-papillary level.The
operating room temperature was kept above 23C, infused
fluids were warmed, a warm humidifier was used and a
warm air forced blanket was applied during the operation.
After sternotomy, PaCO2 , arterial oxygen saturation
(PaO2 ), SjvO2 and haemoglobin (Hb) were measured by
blood sampling at normocarbia (time T1). At the same
time, SaO2 , ET-Isof, BIS, Temp and the haemodynamic vari-
ables cardiac index (CI), SvO2 , mean arterial pressure (MAP)
and systemic vascular resistance index (SVRI) were
recorded. Thereafter, hyperventilation was induced until
E0CO2 was reduced by about 1.3 kPa from its value at T1
and maintained for 10 min; the measurements were then
repeated (time T2).
The difference between PaCO2 and E
0
CO2
was re-evaluated
and ventilation was adjusted to achieve normocarbia. When
the measured PaCO2 indicated normocarbia, ventilation was
maintained for 10 min and all measurements were repeated
(time T3). A loading dose of milrinone 50mg kg
1 was given
over 10 min, and it was then continuously infused at 0.5 mg
kg1 min1 until the end of the study. All the measurements
were repeated 20 min after the loading dose of milrinone
(time T4). Thereafter, hyperventilation was induced until
E0CO2 was reduced by about 1.3 kPa from its value at T4
and maintained constant for 10 min, and then all the meas-
urements were repeated (time T5).
The changes DSjvO2 and DPaCO2 were measured between
T1 and T2, and between T4 and T5. Then CCO2R, expressed
as the percentage change in SjvO2 for a 1 kPa change inPaCO2
(DSjvO2 /DPaCO2 ), and the correlation between DSjvO2 and
PaCO2 were calculated.
If MAP decreased below 60 mm Hg at any time during the
study, norepinephrine was administered and the patient was
excluded. All measurements were performed during harvest-
ing of the internal mammary artery (IMA) and creating the
Y-graft between the IMA and the harvested radial artery.
Data were analyzed using SPSS version 10.0 (SPSS Inc.,
Chicago, IL) and expressed as mean (standard deviation).
The paired t-test was used to compare changes between the
parameters measured at T1 and T2, T3 and T4, and T4 and T5,
and between CCO2R values calculated before and after mil-
rinone administration. The bivariate correlation test and the
linear regression test were used to analyze the relationship
between DSjvO2 and DPaCO2 . A P-value <0.05 was consid-
ered statistically significant.
Results
Patient characteristics are summarized in Table 1. During
the study, MAP was maintained above 60 mm Hg in all
patients without norepinephrine administration. The mean
length of catheter from skin to jugular bulb was 15.5 (SD 0.9,
range 13.5–17.0) cm. All patients were discharged from
the intensive care unit without any neurobehavioural
complications.
During normoventilation, the administration of milrinone
significantly increased CI and SvO2 (both P<0.001), and
decreased MAP and SVRI (both P<0.001), but the change
in SjvO2 was not significant (P=0.58) (Table 2).
Table 1 Patient characteristics (n=30). BSA, body surface area; LVEF,
preoperative left ventricular ejection fraction
Mean (SD) Range
Age (yr) 60.9 (8.2) 50–75
BSA (m2) 1.74 (0.16) 1.36–2.02
Male:female 19:11
No. with diabetes mellitus 16
LVEF (%) 59.8 (10.1) 40–80
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Before and after milrinone administration, hyperventila-
tion significantly decreased PaCO2 and SjvO2 (both P<0.001)
(Table 3). DSjvO2 showed a positive linear correlation with
DPaCO2 before milrinone administration:
DSjvO2=8:5+6:4ðDPaCO2Þ ðR2=0:14,P=0:044Þ
After milrinone administration, hyperventilation signifi-
cantly decreased PaCO2 and SjvO2 (both P<0.001). DSjvO2
showed a positive linear correlation with DPaCO2 after
milrinone administration:
DSjvO2=8:2+5:2ðDPaCO2Þ ðR2=0:15,P=0:039Þ
There was no significant difference between CCO2R before
and after milrinone administration (13.3 (SD 5.7) and 12.3
(SD 3.9)% kPa1, respectively; P=0.46).
There were no significant differences between values of
PaO2 , SaO2 , Hb, ET-Isof, BIS and Temp measured at T1 and
T2, at T3 and T4, or at T4 and T5.
Discussion
In this study, the effect of milrinone on SjvO2 and CCO2R in
patients undergoing CABG was evaluated. Administration
of milrinone did not change SjvO2 and CCO2R, despite an
increase in CI and a decrease in SVRI.
Cerebral oxygenation is determined by the coupling
between CBF and cerebral metabolic rate (CMR). It is
recognized that SjvO2 , as a surrogate marker of the global
cerebral oxygenation,12 –14 reflects the change in CBF, pro-
vided that CMR is kept constant. It can be used to calculate
CCO2R.
15 16 A limitation of SjvO2 monitoring is that small
areas of ischaemia may not be detected. The normal range of
SjvO2 is 60–75%. At SjvO2 >75% CBF is in excess for CMR.
SjvO2 <50% has been associated with increased cerebral
oxygen extraction due to insufficient CBF for CMR, and
has been described after traumatic head injury or intracranial
surgery12 –14 and during the rewarming period of cardiopul-
monary bypass (CPB). It has been related to postoperative
cognitive decline after cardiac surgery.17 18
In this study, milrinone increased CI by 33%, decreased
SVRI by 35% and MAP by 15%, and significantly increased
SvO2 ; however, it did not significantly change SjvO2 at the
same level of PaCO2 . There are two possible explanations for
the unchanged SjvO2 after the administration of milrinone.
Milrinone may not affect CBF and CMR. Although milri-
none induces cerebral artery dilatation and increases CBF in
animal studies,6 7 its effect on SjvO2 in humans with an intact
blood–brain barrier (BBB) is unknown. There are several
studies of the effects of other PDE inhibitors on CBF.
Kruuse and colleagues19 reported that although pentoxiflyl-
line, a non-selective PDE inhibitor that increases cAMP,
dilated the middle cerebral artery (MCA) and temporal
artery, it did not increase regional and global CBF in healthy
subjects. Sildenafil, a PDE5 inhibitor that increases cyclic
guanosine monophosphate (cGMP), did not increase regio-
nal CBF.20 On the other hand, as milrinone is an inodilator
producing an increase in CO and vasodilation, it might have
proportionally increased both CBF and CMR. Milrinone has
been used to reverse cerebral vasospasm following subar-
achnoid haemorrhage.9 10 Yu and colleagues21 reported that
olprinone, another PDE3 inhibitor, increased CO and CBF
through its direct vasodilator effect on the cerebral artery in
patients with an intact BBB. Some animal studies6 –8 suggest
that the vasodilatory action of milrinone induces cerebral
artery dilatation regardless of the integrity of the endothe-
lium. In a human study, the administration of milrinone
increased CBF and the blood flow velocity of MCA by
20%, most likely as a result of cerebral vasodilation.11 How-
ever, as the blood flow velocity of MCA was measured with
transcranial Doppler ultrasonography, which does not
directly measure the quantitative change in CBF, the effect
of milrinone on CBF is unclear. Although milrinone pre-
served the coupling between CBF and CMR, its separate
effects on CBF and CMR were not clarified in this study and
further investigation is needed.
CCO2R is a marker of the ability of the cerebral vascu-
lature to respond to cerebral metabolic demands. Normally
independent of perfusion pressure, CCO2R is influenced by
the cerebrovascular resistance (CVR),22 23 decreasing as
CVR increases. It is known that carbon dioxide freely dif-
fuses across the blood–brain barrier and that changes in
PaCO2 have a positive linear correlation with the changes
in CBF, without affecting CMR, under both awake and
anaesthetized conditions.24 25 In this study, DSjvO2 showed
a significant positive linear correlation with DPaCO2 and
CCO2R was unchanged after milrinone administration.
Table 2 The effect of milrinone on SjVO2 and haemodynamic variables during
normoventilation. Data are mean (SD). ***P<0.001 compared with the value at
T3. PaCO2 and SjvO2 at T4 were not different from the values at T3 (P=0.78 and
P=0.58, respectively)
At T3 At T4
PaCO2 (kPa) 4.7 (0.4) 4.8 (0.3)
SjvO2 (%) 67.3 (5.9) 67.8 (6.5)
CI (l min1 m2) 2.6 (0.6) 3.5 (0.6)***
SvO2 (%) 82.3 (4.4) 86.8 (3.9)***
MAP (mm Hg) 88.4 (11.0) 75.4 (9.8)***
SVRI (dyn s cm5 m2) 2583 (689) 1616 (395)***
Table 3 Changes in PaCO2 and SjVO2 before and after milrinone administration.
Data are mean (SD). ***P<0.001 compared with the value at T1; {{{P<0.001
compared with the value at T4. DSjvO2 /DPaCO2 T4–5 vs T1–2 (P=0.46)
Before milrinone After milrinone
At T1 At T2 At T4 At T5
PaCO2 (kPa) 4.7 (0.4) 3.3 (0.4)*** 4.8 (0.3) 3.6 (0.3)
{{{
SjvO2 (%) 67.0 (5.7) 49.3 (5.8)*** 67.8 (6.5) 53.6 (6.4)
{{{
DSjvO2 /DPaCO2
(% kPa1)
13.3 (5.7) 12.3 (3.9)
Oh et al.
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Therefore it is suggested that milrinone preserves CCO2R. In
particular, since SjvO2 decreased to 53.6% when PaCO2
decreased to 3.6 kPa, careful monitoring and maintenance
of the PaCO2 level within the normocarbia range is necessary
during milrinone administration to prevent cerebral hypo-
perfusion, regardless of the changes in haemodynamics.
In this study, MAP decreased by a mean of 13 mm Hg
after milrinone administration but was maintained
above 60 mm Hg, thus preserving pressure-flow cerebral
autoregulation.25 Since other variables that affect SjvO2 ,
such as PaO2 , SaO2 , Hb, ET-Isof and Temp, were constant
throughout the study, they would not have affected the
result. In this study, high-dose sufentanil and isoflurane
<0.4% were used for anaesthesia. It is known that high-
dose sufentanil preserves not only the coupling between
CBF and CMR, owing to the proportional decrease in
both CBF and CMR, but also CCO2R.
26 27 Although all
inhalation anaesthetics above 1.0 MAC, including isoflur-
ane, are known to impair the coupling between CBF and
CMR, the dose of isoflurane used in this study is known to
have a relatively small effect on the coupling between CBF
and CMR.28 29 The BIS value, indicating the degree of
anaesthetic depth, was kept between 50 and 60 during
this study. Patients with neurological abnormalities, a his-
tory of carotid artery stenosis or severely impaired left ven-
tricular function were excluded. Further studies are needed
to investigate the effect of milrinone on SjvO2 and CCO2R in
these patients.
In conclusion, although milrinone induced significant
haemodynamic changes, SjvO2 and CCO2R were unchanged.
Consequently, maintenance of PaCO2 within the normal
range is important to prevent cerebral hypoperfusion.
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